StemCell Therapy

Chemotherapy induced peripheral neuropathy Pipeline Insight Market Report defines the business objective to help business owners to avoid contradictory expectations. It provides you customer data along with their demands hence you can accordingly plan for the launching of the product in the market. It presents all the data about whole market scenario. With the help of prominent data provided in the Chemotherapy induced peripheral neuropathy Pipeline Insight Market Report, organizations come to know about customers completely and can achieve their goal of selling products in huge quantity and getting huge profits too. Clearly setting the business goal at the beginning will surely help to avoid getting difficulties and set the business easily.

Request sample copy of this report at

https://www.researchforetell.com/reports/64859/chemotherapy-induced-peripheral-neuropathy-pipeline-insight-2021/request

Chemotherapy induced peripheral neuropathy (CIPN): Therapeutic Assessment

This segment of the report provides insights about the different Chemotherapy induced peripheral neuropathy (CIPN) drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Chemotherapy induced peripheral neuropathy (CIPN)

There are approx. 15+ key companies which are developing the therapies for Chemotherapy induced peripheral neuropathy (CIPN). The companies which have their Chemotherapy induced peripheral neuropathy (CIPN) drug candidates in the most advanced stage, i.e. phase II include, MediciNova.

Phases

DelveInsight s report covers around 15+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Chemotherapy induced peripheral neuropathy (CIPN) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

intravitreal

Subretinal

Topical.

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Chemotherapy induced peripheral neuropathy (CIPN): Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Chemotherapy induced peripheral neuropathy (CIPN) therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chemotherapy induced peripheral neuropathy (CIPN) drugs.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Chemotherapy induced peripheral neuropathy (CIPN) R&D. The therapies under development are focused on novel approaches to treat/improve Chemotherapy induced peripheral neuropathy (CIPN).

In December 2019, Solasia Pharma entered into an exclusive license agreement with Maruho for commercialization of Solasia s product SP-04 (PledOx , hereinafter product ), a therapeutic agent for chemotherapy induced peripheral neuropathy (currently undergoing Phase III clinical trials) in Japan.

Chemotherapy induced peripheral neuropathy (CIPN) Report Insights

Chemotherapy induced peripheral neuropathy (CIPN) Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Chemotherapy induced peripheral neuropathy (CIPN) Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Chemotherapy induced peripheral neuropathy (CIPN) drugs

How many Chemotherapy induced peripheral neuropathy (CIPN) drugs are developed by each company

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Chemotherapy induced peripheral neuropathy (CIPN)

What are the key collaborations (Industry Industry, Industry Academia), Mergers and acquisitions, licensing activities related to the Chemotherapy induced peripheral neuropathy (CIPN) therapeutics

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies

What are the clinical studies going on for Chemotherapy induced peripheral neuropathy (CIPN) and their status

What are the key designations that have been granted to the emerging drugs

Key Players

NeuroBo Pharmaceuticals

Aptinyx

Midatech Pharma

MediciNova

Sonnet BioTherapeutics

Toray Industries

EA Pharma

AnnJi

Asahi Kasei Pharma

PledPharma

Key Products

NB-01

NYX-2925

KRN5500

MN-166 (ibudilast)

SON-080

TRK-750

EA4017

AJ302

SP-04

Thrombomodulin alfa

Calmangafodipir

Inquire for a discount at

https://www.researchforetell.com/reports/64859/chemotherapy-induced-peripheral-neuropathy-pipeline-insight-2021/discount

Key Features of the Report:

Complete report is available at

https://www.researchforetell.com/reports/64859/chemotherapy-induced-peripheral-neuropathy-pipeline-insight-2021

About Us

Research Foretell is an information service company that provides market research, custom, and consulting services. Decision-making is complicated and we help you to solve your biggest puzzle, by identifying, analyzing, and monitoring the recent developing technologies and markets. Research Foretell is always forefront on classifying new opportunity in the market; with us you always have the first mover advantage.

Contact Us:

Robert Claussen (Head of Sales)

Phone: +91-81499-24059

Email: sales@researchforetell.com

Read more:
Chemotherapy induced peripheral neuropathy Pipeline Insight to See Strong Expansion Through 2027 Covid-19 Analysis The Courier - The Courier

This entry was posted on May 14, 2021 at 1:54 am and is filed under Neuropathy. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |